Melphalan With or Without Siltuximab
Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 215 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Recordati Pharmaceutical company
- Tags
- Monoclonal Antibody, Interleukin 6 (IL-6), Post-Autologous Stem Cell Transplant, Pre-Autologous Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2018
- NCT Identifier
- NCT06679829
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.